Recent News

FDA Approves Pembrolizumab Plus Axitinib in Advanced Kidney Cancer

Does Bladder-Sparing Therapy Plus Vinorelbine Improve Survival in Cisplatin-Ineligible Patients?

Accelerated FDA Approval Granted to Erdafitinib for Metastatic Urothelial Carcinoma

AACR 2019: Can B Cells Predict Response to Immunotherapy in Renal Cell Carcinoma?

EAU Congress 2019: Early Menopause in Smokers and Bladder Cancer Risk

Tumor-Lysis Syndrome in Patients With Genitourinary Cancers

Nivolumab in Metastatic Kidney Cancer in ‘Real-World Setting’

Predicting Outcomes With Lung Immune Prognostic Index

Postoperative Chemotherapy Plus Radiotherapy for Locally Advanced Bladder Cancer

2019 GU Symposium: Subgroup Analysis of Avelumab + Axitinib in JAVELIN Renal 101 Trial

2019 GU Symposium: Tivozanib Versus Sorafenib in Advanced Renal Cell Carcinoma

Priority Review Granted to Pembrolizumab Combination in First-Line Therapy for Advanced Kidney Cancer

FDA Accepts for Priority Review Avelumab and Axitinib Combination for Advanced Kidney Cancer

2019 GU Symposium: Cabozantinib vs. Everolimus in METEOR Trial of Kidney Cancer

2019 GU Symposium: Pembrolizumab Plus Axitinib Versus Sunitinib in Advanced Kidney Cancer

Risk Factors for Renal Cell Carcinoma Related to Obesity

Computer-Designed Protein Mimics Interleukin-2 With Less Toxicity

Kidney Cancer and Rare Genetic Tumor Syndrome

Sorafenib Versus Other Targeted Agents in Metastatic Renal Cell Carcinoma

Northwestern Medicine Receives $10 Million Gift to Create Urologic Cancer Institute

TKIs After Immunotherapy Failure in Metastatic Renal Cell Carcinoma

Predicting Prognosis for Patients With Metastatic Papillary Renal Cell Carcinoma

Clinical Trial of Personalized Vaccine in Kidney Cancer Commences

Validated Risk Model Integrates Molecular Features in Advanced Renal Cancer

Annexin A1 Expression in Renal Cell Carcinoma

Identifying Optimal Dose of Cyclophosphamide With Everolimus in Metastatic Kidney Cancer

Pegilodecakin Plus Anti–PD-1 Therapy for Renal Cell Carcinoma

ATLAS Trial: Axitinib in Patients at High Risk of Recurrence of Kidney Cancer

Exploring the Mechanism of MTAP Regulation in Renal Cell Carcinoma

Kidney Week 2018: Does Diabetes Increase the Risk for Renal Tumorigenesis?

Breakthrough Therapy Designation Granted by FDA to UGN-101 in Urothelial Cancer

ESMO 2018: Cabozantinib in PD-L1–Unselected Patients With Metastatic Kidney Cancer

ESMO 2018: In Kidney Cancer, Response to Treatment Varies With Gene Expression

ASTRO 2018: Stereotactic Ablative Radiotherapy for Patients With One Kidney

ESMO 2018: Novel First-Line Combination Therapy for Advanced Kidney Cancer

Kidney Week 2018: Shedding Light on Origin of Papillary Kidney Cancer

ASTRO 2018: Toxicity of Stereotactic Body Radiation Therapy in Primary Kidney Cancer